SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ:AFFX) today announced the launch of its Genome-Wide Human SNP Array 6.0, a single microarray that measures more than 1.8 million markers for genetic variation—close to three times the content of currently available competing products. The array enables researchers to perform the most powerful whole-genome association studies ever by genotyping more markers from more individuals at a lower cost per sample. These higher-powered studies increase the probability of discovering genes associated with adverse drug response or complex diseases, such as Alzheimer's, diabetes, heart disease and Parkinson's.
